1. Medtech Insight
  2. >>Digital Technologies

QUOTED. 6 May 2020. David Stavens.

Nines recently became the first company to gain 510(k) clearance from the US FDA to market an algorithm-based software solution called NinesAI that allows radiologists to triage intracranial hemorrhage and mass effect on CT scans from non-emergent cases. See what Nines’ CEO David Stavens said about it here.

Quoted

“It allows emergent cases to be seen faster, which improves the quality of care and also reduces the cost of care, because if emergencies are seen faster, they are more cost-effective to treat.” – David Stavens, CEO, Nines

Click here for a free trial of Medtech Insight

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.